Market Herald logo


Be the first with the news that moves the market
  • HeraMED has provided updates regarding the trials of its HeraBEAT and HeraCARE PRO devices
  • The trials were undertaken with Brazil’s largest healthcare provider Hapvida Saude
  • HeraBEAT and HeraCARE PRO platform are now operational at multiple locations and are being used by medical professionals

Medical technology company HeraMED has provided updates regarding trials of its foetal heart rate monitor HeraBEAT and its pregnancy monitoring platform HeraCARE PRO.

These trials were undertaken with one of Brazil’s largest healthcare providers, Hapvida Saude.

Hapvida is both a healthcare provider and medical insurance company, servicing over 6.5 million customers annually. This is done through its network of 100 hospitals and 1000 clinics across 11 states.

Following the successful integration of HeraCARE PRO into Hapvida’s IT systems, HeraMED has advised that its HeraBEAT devices and HeraCARE PRO platform are now operational at multiple locations and are being used by medical professionals.

“Having multiple HeraBEAT monitors and HeraCARE subscriptions deployed and operational across Hapvida’s network marks a significant achievement for HeraMED,” CEO and Co-founder David Groberman said.

“The broader pilot trial with Hapvida will utilise HeraCARE PRO and HeraBEAT to provide a cost-effective and more accurate pregnancy monitoring offering to patients and medical professionals in Brazil,” he said.

HeraMED is now observing seamless data upload and sharing between the HeraBEAT monitors and the HeraCARE PRO platforms.

This development outlines the potential adaptivity of both solutions and further validates HeraMED’s potential with large scale medical organisations.

HeraBEAT is a medically accurate, scientifically optimised, smartphone-based heartbeat monitor for home use. Essentially, the monitor allows expectant mothers to monitor their foetus’ heartbeat anytime, anywhere.

This data can then be stored and shared to medical professionals which enables parents to rest easy while they know their foetus is receiving accurate and professional medical attention.

HeraBEAT has already passed multiple clinical trials and secured approval from key regulatory bodies in Australia, Israel, and Europe.

Both Hapvida and HeraMED remain in ongoing discussions regarding platform updates and optimisation.

Both companies will aim to utilise the solutions during the intrapartum phase of pregnancy — the period spanning childbirth to the onset of labour — and if successful they will provide even greater value to the platforms and could potentially underpin increased uptake.

HeraMED will remain in ongoing discussions with Hapvida’s medical professionals to gather feedback on the HeraBEAT device and HeraCARE PRO solution.

Updates will be provided as the trial progresses.

HMD by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.